원문 보기
hey guys it is julie here with tip ranks in today's video we're taking a look at two stocks that are held by kathy woods arc invest so let's get into it all right guys welcome back and thank you all so much for being here today we're taking a look at two growth stocks that not only have a place in kathy woods arc invest etfs but also come in as strong buy ratings from analysts with some pretty attractive upside so in today's video we're going to take a look at these two companies what it is that they do and what analysts are predicting for their stock's future just before we get into all of that this is your friendly reminder that if you enjoy today's video make sure you hit that thumbs up button and let your subscribe to the channel as well okay let's dive right into these two stocks the first company on our list today is verve therapeutics they trade under the ticker v-e-r-v and are currently priced at 62.65 cents per share verve therapeutics focuses on heart disease a leading cause of preventable death they aim to develop and market new therapies for heart disease that are both transformative and once and done verve uses a novel approach to cardiovascular disease treatment based on single course in vivo liver directed gene editing treatments designed to attack the root cause of heart disease the company's pipeline features two drug candidates both which are in pre-clinical development phase the leading candidate of the two verve 101 is under development for patients with hefh a genetic mutation that leads to high low density lipid ldl ldlc levels in the blood and eventually arterial blockage these are lead causes of heart attack and stroke and a once and done treatment would mark an advance for patients currently on long-term medication courses to raise capital for further research verve just hit the public market this summer the stock went public in june when they released about 14 million shares set at a 19 price target this was higher than the 16 to 18 range expected ferv raised over 306 million dollars in gross proceeds from their ipo the stock closed its first day of trading at 31 dollars per share and has doubled since then arc invest purchased about 550 000 shares of the verve stock a position which is worth about 34 million dollars today one analyst feeling bullish on the verve therapeutic stock is etzer de root from guggenheim he says that although verve is still in the early stages of development we believe the company's single course treatment has an opportunity to transform the chronic treatment and management of atherosclerosis and our risk-adjusted mpv assumptions for familiar hypocholesterolomia alone a subset of atherosclerotic individuals at higher risk of developing cardiovascular disease justify current levels we expect pre-clinical updates from verve 101 including long-term durability data in non-human primates over the next 12 to 18 months as well as positive updates from other gene editing programs to provide validation of verv's platform and a path to potential near and longer term upside etzer is one of four analysts that currently have a rating on the verve stock and it does come in as a strong buy this is based on three buy ratings and one hold the average price target comes in at 68.67 per share at current prices this would be an upside potential of 9.6 percent now we do have a hold rating that has a downside of 20 and on the high end we have etzer's price target of 84 dollars per share which would be a growth potential of nearly 34 the second company that we're taking a look at is probably a bit better known that is draftkings trading under the ticker dkng they're currently priced at 59.46 draftkings specializes in the world of online fantasy sports and sports betting they are a major source of entertainment for sports fans worldwide offering them vicarious participation and a chance to experience the risk inherent in the game in recent months the company has added online casino gaming and lottery games to its sports betting and fantasy league offerings draftkings has partnerships and works alongside pretty much all of the major sports leagues and sports outlets just last month draftkings made the notable acquisition of golden nugget adding the golden nugget enables greater eye gaming market share potential while being more efficient with marketing and having multiple brands serving different customer segments the golden nugget also has a very strong live dealer operational capabilities which are difficult to develop and an important part of growing the igaming portfolio they're expecting resulting synergies of about 300 million dollars in ebeda also at the beginning of last month draftkings shared their second quarter earnings report they posted 298 million dollars in total revenue which was up 297 year-over-year looking forward they've bumped up their fiscal 2021 revenue guidance from the range of 1.05 to 1.15 billion up to 1.21 to 1.29 billion dollars achieving this will translate to year-over-year revenue growth of 88 to 100 percent kathy woods arkan vest already had a position in draftkings so their most recent purchase was just an expansion of their position size and it was a notable expansion at that they bought over 9 million shares which was an increase of 212 percent their total position in draftkings is now over 13 and a half million shares that adds up to a healthy 800 million dollar position one analyst weighing in on the stock is daniel pollitzer from jp morgan he says that our favorable view of draftkings reflects its position as a leading platform in ussb and igaming which we view as the most attractive growth vertical in gaming their potential upside to their current 17 i gaming share as the company integrates golden nugget fine-tunes its products and targets casino first customers systematic buildup of highly differentiated full-scale sports betting and media offering and strong cross-sell capabilities now the draftking stock has a total of 17 analyst ratings and does come in as a strong buy based on 13 buy ratings and four holds the average price target comes in at 72.75 which would be a 22 upside from current prices on the low end we do have our hold ratings with one at 51.
which would be a 14 downside and the highest price target comes from daniel at loop capital at 105 that would be a 76 growth potential so there are two great growth stocks held in kathy woods arc invest etfs of course i always love hearing from you guys so let me know your thoughts on these two companies or what other kathy wood holdings you love i know she has a ton of great stocks within her etfs so make sure to share your thoughts in the comments down below as always keep in mind that these videos are never a suggestion to buy or sell any specific stock and are just meant for information and entertainment purposes please always make sure you're doing your own research and due diligence before making any investment decision if you mean it to the end of today's video make sure you hit that thumbs up button and that you're subscribed to the channel as well thank you guys so much for watching and i'll see you back here next time
댓글 0